To date, global pharmaceutical companies have not shown a keen interest in the cannabis industry — some believe that is due purely to the limited opportunity for patents. “The patent potential of cannabis is restricted to certain formulations, not the kind of products that are currently available through the ACMPR,” said Phillipe Lucas, Tilray’s Vice-President of Patient Research and Advocacy. “In fact, patents in methods of delivery have already been claimed by others,” he added.
I’d like to think OWCP is being referred(partially) to in this paragraph. IMO this makes us pretty attractive to a large Pharma.